In line with our hypothesis, transfection of synthetic miR-214 antagonist led to a significant decrease in ISO-induced ERK1/2 MAPK activation, indicating that miR-214 could be a critical regulator of ERK1/2 MAPK activity in CFs. This evidence concerns the gene MAPK3 and myalgic encephalomeyelitis/chronic fatigue syndrome.